| Pontos | Posição | |
|---|---|---|
| CEF.UP+NIPE (average of all rankings) (2012) | 5.63 | 465/501 |
| Australian RC (2010) | 25.0 | 444/479 |
| CNRS (2008) | 20.0 | 314/336 |
| Ideas discounted recursive impact factor (2012) | 0.2 | 347/396 |
| Source Normalized Impact per Paper (SNIP) (2011) | 5.69 | 375/476 |
| Article Influence Score (2021) | 1.07 | 176/409 |
| Impact Factor (2021) | 3.69 | 126/409 |
| Impact Factor (2019) | 2.44 | 112/440 |
| Impact Factor (5 year) (2021) | 3.67 | 128/409 |
| SJR - Scimago (2021) | 0.94 | 215/558 |
| SJR - Scimago (2019) | 0.92 | 220/549 |
| Count (2021) | 1.0 | 204/662 |
Avoiding Opportunity Cost Neglect in Cost-Effectiveness Analysis for Health Technology Assessment
James Lomas,
Jessica Ochalek,
Rita Faria
vol. 20, 2022, p. 13-18.
Inference Procedures to Quantify the Efficiency-Equality Trade-Off in Health from Stated Preferences: A Case Study in Portugal
Micaela Pinho,
Anabela Botelho
vol. 16, 2018, p. 503-513.
Cost-Effectiveness Analysis of Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukaemia in Portuguese Patients Who Are Unsuitable for Full-Dose Fludarabine-Based Therapy
Ana Teresa Paquete,
Luis Silva Miguel,
Ursula Becker,
Catarina Pereira,
Carlos Gouveia Pinto
vol. 15, 2017, p. 501-512.
Cost-Effectiveness Analysis of 3-D Computerized Tomography Colonography versus Optical Colonoscopy for Imaging Symptomatic Gastroenterology Patients
Manuel Gomes,
Robert W. Aldridge,
Peter Wylie,
James Bell,
Owen Epstein
vol. 11, 2013, p. 107-117.
Cost-Effectiveness Analysis of Boceprevir for the Treatment of Chronic Hepatitis C Virus Genotype 1 Infection in Portugal
Elamin H. Elbasha,
Jagpreet Chhatwal,
Shannon A. Ferrante,
Antoine C. El Khoury,
Pedro A. Laires
vol. 11, 2013, p. 65-78.